Heart Failure

Karol Watson, MD, shares her professional and personal perspective on what a prophylaxis means for especially older VTE patients.

What the Type 2 diabetes treatment could do if approved for cardiovascular events, according to Karol Watson, MD.

A meta-analysis provides no support for theory that incretin-based treatment causes increased mortality in patients with T2D.

Despite its recent success, Morgan Stanley experts give the drug 5% odds of reaching markets.

The drug reduced cardiovascular risk in people with prior heart attack and inflammatory atherosclerosis.

The CANVAS results yield promise against cardiovascular events, but a risk of amputations.

Benefit was seen in 5 countries regardless of SGLT2 inhibitor used.

85% of patients experienced improvement in heart failure symptoms

The FDA determined Sentinel is effective in capturing debris caused by TAVR.

Researchers have been investigating whether PCSK9 inhibitors can protect other patients at high risk for a cardiovascular event.

At AAPA 2017 in Las Vegas, Jennifer Carlquist PA-C, ER, CAQ said that she believed clinicians are trained in medicine to think heart disease is "an old person's disease," so they don't have it on their radar for the young people (teen years through mid-30s).

What should the new priorities be in congenital heart disease research?

Study results also showed that levosimendan did not positively affect secondary outcome measures compared to placebo.

Results of a new study indicate an unrecognized systolic dysfunction.

SGLT-2i medicines reduce heart failure hospitalization by 39%.

Even so-called “healthy obese†people have increased risk of heart failure.

Researchers studied administrative claims data from over a year.

The dual endothelin receptor antagonist caused early fluid retention.

A German study examined the intestinal microbiomes of 20 HF patients.

AF is linked with increased risks of stroke, dementia, and heart failure.

After decades of decline, heart disease mortality is on the rise again.

Exercise training had positive anti-arrhythmic effects in patients with AF.

PCPs must be aware of all potential therapies to help reduce the burden of HF.

Treating systolic blood pressure of >120 mmHG reduces risk of acute decompensated heart failure.

Delaying LVAD therapy found not to impair survival, according to new study results.

Heart failure is diabetes’ most sinister, most overlooked complication

Abnormal HRV parameters may be associated with incident CHF in asymptomatic older adults.

High BMI in midlife may lead to higher risk of hospitalization for heart failure.